Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.57 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11969735 | 1.00 | CYSLTR2 (0.57) | CYSLTR2CYSLTR1 | |
| SCHEMBL692811 | 1.00 | CYSLTR2 (0.57) | CYSLTR2CYSLTR1 | |
| SCHEMBL692812 | 1.00 | CYSLTR2 (0.57) | CYSLTR2CYSLTR1 | |
| SCHEMBL4300160 | 1.00 | CYSLTR2 (0.57) | CYSLTR2CYSLTR1 | |
| Water SCHEMBL3030652 | 0.99 | CYSLTR2 (0.56) | CYSLTR2CYSLTR1 | |
| Water SCHEMBL3030658 | 0.99 | CYSLTR2 (0.56) | CYSLTR2CYSLTR1 | |
| SCHEMBL13381684 | 0.92 | — | — | |
| SCHEMBL30360356 | 0.92 | — | — | |
| SCHEMBL9583242 | 0.92 | — | — | |
| SCHEMBL30360325 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2288595-B1 | AN IMPROVED PROCESS FOR PREPARING MONTELUKAST AND SALTS THEREOF | LAURUS LABS PRIVATE LTD (IN) | 2016-11-02 | — | — | EP | disclosed |
| WO-2010064257-A1 | NOVEL INTERMEDIATES FOR PRODUCING [R-(E)]-1-[[[1-[3-[2-(7- CHLORO -QUINOLINYL)ETHENYL]PHENYL]-3-[2-(1-HYDROXY- METHYLETHYL) PHENYL]PROPYL]THIO] METHYL] CYCLOPROPANEACETIC ACID, MONOSODIUM SALT AND PROCESS THEREOF | INNOGENT LABORATORIES PRIVATE LIMITED (IN) | 2010-06-10 | — | — | WO | disclosed |
| WO-2009144742-A2 | AN IMPROVED PROCESS FOR PREPARING MONTELUKAST AND SALTS THEREOF | APTUIT LAURUS PVT LIMITED (IN) | 2009-12-03 | — | — | WO | disclosed |
| US-20090171092-A1 | Process for the Preparation of Montelukast and Its Pharmaceutically Acceptable Salts | MSN LABORATORIES LIMITED (IN) | 2009-07-02 | — | — | US | disclosed |
| US-20060004204-A1 | Process for preparation of montelukast and its salts | REGURI BUCHI R | 2006-01-05 | — | — | US | disclosed |
| US-20050107612-A1 | Process for preparation of montelukast and its salts | DR. REDDY'S LABORATORIES LIMITED | 2005-05-19 | — | — | US | disclosed |
| EP-0500360-B1 | Quinoline-containing ketoacids as leukotriene antagonists | MERCK FROSST CANADA INC (CA) | 1997-06-25 | — | — | EP | disclosed |
| US-5212180-A | Quinoline-containing ketoacids as leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1993-05-18 | — | — | US | disclosed |
| EP-0500360-A1 | Quinoline-containing ketoacids as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1992-08-26 | — | — | EP | disclosed |
| EP-0480717-A1 | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1992-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107612-A1 | Process for preparation of montelukast and its salts | MPST, CMA1, TPMT | CYSLTR2 27/4885CYSLTR1 18/4885 |
| US-20090171092-A1 | Process for the Preparation of Montelukast and Its Pharmaceutically Acceptable Salts | CMA1, TPSD1, AP1S1 | CYSLTR2 32/4885CYSLTR1 23/4885 |
| US-20060004204-A1 | Process for preparation of montelukast and its salts | MPST, CMA1, TPMT | CYSLTR2 27/4885CYSLTR1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.